aTyr Pharma Inc Sustainability Reports

aTyr Pharma Inc. is a clinical-stage biotechnology company engaged in the discovery and development of innovative medicines based on tRNA synthetase biology. Its primary candidate is efzofitimod, which is being evaluated for the treatment of interstitial lung diseases.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 529900ENQUXMC5EBKO36

FIGI: BBG001V0GF01

6 reports from 2016 to 2023

• aTyr Pharma Inc 2023 Annual Report on Form 10-K
• aTyr Pharma Inc 2022 Annual Report on Form 10-K
• aTyr Pharma Inc 2021 Annual Report on Form 10-K
• aTyr Pharma Inc 2018 Annual Report on Form 10-K
• aTyr Pharma Inc 2017 Annual Report on Form 10-K